Author/Editor		Zver, Samo; Modic, Mojca; Žontar, Darja
Title		Opredelitev akutnih limfoblastnih levkemij s celičnimi imunološkimi označevalci
Translated title		Immunological classification of acute lymphoblastic leukemias
Type		članek
Source		Zdrav Vestn
Vol. and No.		Letnik 71, št. 5
Publication year		2002
Volume		str. 303-6
Language		slo
Abstract		Background. ALL is a malignant blood disease and lymphoblasts have origin in B or T lymphatic cell line. In 1997 established new World Health Organisation classification (WHO classification) of malignant heamatological diseases realizes the importance of cellular immunological markers (immunophenotype) and chromosomal abnormalities (cytogenetics). Based on both findings we may distribute the patients in low, intermediate and high risk groups and the outcome of such distribution is risk adopted ALL treatment strategy. On Clinical department of haematology (CDH) we have decided to overview immunophenotype characteristics of all ALL patients during the January 1, 1995-December 31, 2001 period. Methods and results. During the January 1, 1995-December 31, 2001 period on CDH we have treated 44 patients: 22 males and 22 females. With flow cytometer Coulter Epics XL MCS we have performed first primary antibody panel for acute leukemias antigens (CD2, CD7, CD10, CD19, CD34, cCD3, cCD13, cCD22, MPO, TdT), followed by secondary panel. The later have included antigen CD20, CD23, membrane and/or cytoplasmatic immunoglobulins or their light chains monoclonal antibodies for B-ALL and antigen CD3, CD4, CD5 and CD8 monoclonal antibodies for T-ALL subsets. Besides immunophenotyping we have evaluated all ALL patients also morphologically according to FAB classification (French-American-British classification), which is an old classification based solely on morphology. 32/44 (73%) patients have had immunophenotypic B-ALL, and 12/44 (27%) T-ALL. Subgroups distribution of B-ALL immunophenotype were: pro-B 4/44 (9%), "common"-B 18/44 (41%), pre-B 5/44 (11.5%) and mature B 5744 (11.5%) and for T-ALL imunophenotype were: pro-T 2/44 (4.5%), pre-T 5/44 (11.5%), cortical-T 4/44 (9%) and mature-T 1/44 (2%). (Abstract truncated at 2000 characters).
Summary		Izhodišča. Akutna limfoblastna levkemija (ALL) je rakava krvna bolezen, limfoblasti pa lahko izvirajo iz limfatične vrste B ali T. Leta 1997 sprejeta razvrstitev malignih krvnih bolezni Svetovne zdravstvene organizacije (klasifikacija WHo) pri ALL poudarja pomen celičnih imunoloških označevalcev (imunofenotip) in kromosomskih nepravilnosti (citogenetika). Na osnovi obeh preiskav lahko napovemo potek bolezni in bolnike razvrstimo v skupine z nizkim, srednjim in visokim tveganjem, stopnja tveganja pa vpliva na odločitev o zdravljenju. Na kliničnem oddelku za hematologijo (KOH) smo zbrali in pregledali imunofenotipske značilnosti bolnikov z ALL, ki so se pri nas zdravili v obdobju 1.1.1995 - 31.12.2001. Metode in rezultati. V obdobju 1.1.1995 - 31.12.2001 se je na KOH zdravilo 44 bolnikov z ALL: 22 moških in 22 žensk. Na pretočnem citometru Coulter Epics XL-MCL smo pri vseh bolnikih na podlagi določitve antigenov s pomočjo primarnega panela protiteles (CD2, CD7, CD10, CD19, CD34, cCD3, cCD13, cCD22, MPO, TdT) določili ALL B ali T. S sekundarnim panelom monoklonskih protiteles, ki je za B-ALL vključeval antigene CD20, CD23, imunoglobuline in lahke verige, za T-ALL pa CD3, CD4, CD5, CD8, smo bolezen razvrstili v podskupine. Poleg imunofenotipa smo ALL opredelili tudi morfološko po razvrstitvi FAB (French-American-British classification), ki ne upošteva imunofenotipa in citogenetike. Imunofenotipsko B-ALL smo ugotovili pri 32/44 (73%) bolnikov, T-ALL pa pri 12/44 (27%) bolnikov. (Izvleček prekinjen pri 2000 znakih).
Descriptors		LEUKEMIA, LYMPHOCYTIC, ACUTE IMMUNOPHENOTYPING FLOW CYTOMETRY ANTIBODIES, MONOCLONAL LEUKEMIA, B-CELL, ACUTE LEUKEMIA, T-CELL, ACUTE RETROSPECTIVE STUDIES